|
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical research trials and 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases clinical trial. Participants oftentimes recieve the most expert healthcare available for their 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "4" Clinical Trials Conditions > 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases  41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
For Condition: Rheumatic Diseases
Status: No longer recruiting
Sponsor(s): National Center for Research Resources (NCRR) ,
Synopsis: Recently a non-toxic system for whole body hyperthermia (WBH) used at the University of Wisconsin has been shown to induce soluble tumor necrosis factor-receptor (sTNF-R) I and II when patients are heated systemically to 41.8C for 60 minutes. This observation might provide a biological basis for the therapeutic application of WBH to rheumatoid diseases, for which there is a positive anecdotal clinical experience. Inherent in the hypothesis which is the basis for this protocol is the concept that the induction of TNF receptors by WBH may induce a remission in patients with active rheumatoid arthritis. Beyond clinical response the biological endpoint for this investigation includes cytokine levels, TNF levels, sTNF-R levels and changes in cellular TNF receptors.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Parallel Assignment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients are required to meet the criteria of the American College of Rheumatology (ACR)for rheumatoid arthritis. - Patients should be in functional class II, or III according to the criteria of the ACR. - All candidates must be unsuccessfully treated (lack of efficacy) with at least two of the following disease-modifying antirheumatic drugs: hydroxychloroquinine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine. - Patients receiving nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids (<= 10 mg per day), or both are eligible if the dosage has been stable for at least four weeks before treatment and remained so throughout the study and follow-up period (the use of narcotics for pain flares is allowed). - The necessary degree of disease activity at enrollment should be confirmed by a finding of 10 or more swollen joints, 12 or more tender joints, and one of the following two criteria: a Westergren erythrocyte sedimentation rate of at least 28 mm per hour or a serum C-reactive protein level of more than 2.0 mg per deciliter; or morning stiffness for at least 60 minutes. - Patients must have adequate bone marrow function, adequate liver function, adequate renal function, calcium and electrolytes. - Patients must have a dobutamine stress ECHO, or exercise cardiac MUGA, or exercise ECHO scan prior to entry and must fulfill certain criteria to be eligible. The spirit of the criteria are to rule out organic heart disease. - Respiratory status: Patients who have FEV1 of >= 60% of predicted, as well as a maximum voluntary volume (MVV) of >= 60% of predicted, and blood gases with a PO2 of >= 60 or oxygen saturation of >= 90% are eligible.
Total Enrollment:
Location and Contact Information:
K4/666 CSC 600 Highland Av
Madison, Wisconsin, 53792
United States
Additional Information:
Study ID Numbers: NCRR-M01RR03186-9943; M01RR03186
Study Start Date:
Record last reviewed: November 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000106
Other Rheumatic Diseases Studies:
1. Study of Families with Twins or Siblings Discordant for Rheumatic Disorders
2. Blood Component Collection from Patients with Rheumatic Disease and Healthy Volunteers
3. 41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
4. Improving Vocational Outcomes in Arthritis
5. Health Beliefs and Health Behaviors Among Minorities with Rheumatic Diseases
Related Studies:
Other Rheumatic Diseases Clinical Trials
Other Wisconsin Clinical Trials
Other Madison Clinical Trials
41.8 degree Centigrade whole body hyperthermia for the treatment of Rheumatoid diseases
|
|
|
|
|
|
|
|
